About Ascendis Pharma
Ascendis Pharma is a publicly listed company based in Hellerup (Denmark) founded in 2007. Long-acting prodrug therapies are developed for endocrine and rare diseases. Ascendis Pharma has raised $108.7 million across 3 funding rounds from investors including Orbimed, Janus Henderson Investors and RA Capital. Its chief executive, as recorded, is Jan Moller Mikkelsen. Its website ascendispharma.com draws about 19 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals, Drugs, Life Sciences and Immunotherapy. Its legal entity is ASCENDIS PHARMA A/S.
Company details
Ascendis Pharma was founded in 2007 in Hellerup, Denmark, as a biopharmaceutical company focused on prodrug technologies. Unmet medical needs are addressed through a pipeline that includes TransCon human growth hormone for growth hormone deficiency in adults and children, TransCon Treprostinil for pulmonary arterial hypertension, TransCon Insulin for diabetes, and TransCon Ranibizumab for age-related macular edema. Strategic collaborations are maintained with Sanofi and Genentech to support development efforts.
- Headquarters Hellerup, Denmark
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ascendispharma.com
- Social LinkedIn X
- Legal Name Ascendis Pharma A/S Sponsored Adr
- Annual Revenue$812.73 M (USD)106.62as on Dec 31, 2025
- Net Profit-$257.35 M (USD)37.07as on Dec 31, 2025
- EBITDA-$133.82 M (USD)52.61as on Dec 31, 2025
- Total Equity Funding$108.7M (USD)
in 3 rounds
- Latest Funding Round$60M (USD), Series D
Nov 2014
- InvestorsOrbimed
& 11 more
Funding Insights of Ascendis Pharma
Ascendis Pharma has successfully raised a total of $108.7M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $60 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108.7M
- Total Rounds 3
- Last Round Series D — $60M
- First Round $25.8M
(Dec 2007)
- Investors Count 12
All 3 funding rounds of Ascendis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | $60M | Series D | – | Sofinnova Investments, Orbimed | |
| Jun 2010 | $22.9M | Series B | – | – | |
| Dec 2007 | $25.8M | Series A | – | Gilde Healthcare, TechnoStart | – |
12 investors in total: 12 institutional.
Investors in Ascendis Pharma
Ascendis Pharma has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
| technostart.com |
Investor details for Ascendis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ascendis Pharma
349 people are tracked at Ascendis Pharma (217 in leadership, 5 in board & advisors, 127 in team).
| Name | Role | Group |
|---|---|---|
Jan Moller Mikkelsen | CEO & President | Leadership |
Carol Zhao | Head Of Biostatistics, Medical Affairs | Leadership |
Bolette Nordby | Director, Medical Devices, Quality Assurance | Leadership |
Rasmus Haahr | Head Of Combination Product Strategy & Connected Health | Leadership |
Mathias Niemann Johansen | Associate Director, IT Product Ownership | Leadership |
Nikolaj Neerstrand Rasmussen | Director, Biologics Manufacturing | Leadership |
Kim Abbasi | Senior Director, US Marketing | Leadership |
Chris Dobberpuhl | Director, US Market Access | Leadership |
Becky Abens | Senior Director, U.s. Compliance | Leadership |
Telma Lança | Associate Director, Immuno-oncology | Leadership |
Thomas A. Larson | SVP & Chief Commercial Officer | Leadership |
Bart Lubberts | Medical Director - Clinical Development | Leadership |
Mikkel Bøgvad Okholm | Associate Director Of Finance BI | Leadership |
Freja Aksel Jacobsen | Director, QA Commercial Distribution | Leadership |
Jay Donovan Wu | EVP, President US Market | Leadership |
Anita Walsh | Senior Director Of Marketing, Skytrofa | Leadership |
Peggy Neidig | West Director Field Reimbursement | Leadership |
Tommy Kok Annfeldt | Associate Director, Global Medical Information | Leadership |
Annette Derouin | Senior Director, Global Trial Strategy & Support | Leadership |
Thomas Kratz | Director, Global Regulatory Lead | Leadership |
329 more people are available in the full profile.
Complete people profiles for Ascendis Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Ascendis Pharma
Ascendis Pharma is a publicly listed company on the NASDAQ with ticker symbol ASND in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Jan 2015
- Listed onNASDAQ: ASND
- Listed entityAscendis Pharma A/S Sponsored ADR
- Exchange sectorHealth technology
- ISINDK0060615755
- Share price$223.21 (-1.67% on the day) · 2026-10-13
- Market capitalisation$13.92B
- Price to earnings17.0
- EPS (diluted, trailing year)$13.12
- Volume (last session)592,246
Financials of Ascendis Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $812.7M | -$257.4M | -$133.8M |
| 2024 | $393.4M | -$409.0M | -$282.4M |
| 2023 | $288.4M | -$520.5M | -$472.1M |
| 2022 | $53.8M | -$612.9M | -$571.6M |
| 2021 | $9.2M | -$453.4M | -$515.8M |
Detailed financial statements for Ascendis Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ascendis Pharma
4 dated milestones of Ascendis Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ascendis Pharma is founded.
- Funding First funding round of $25.8M.
- Funding Latest funding round, Series D, of $60.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Ascendis Pharma
The website of Ascendis Pharma (ascendispharma.com) receives about 19.2K visits a month and ranks #1,138,420 among all websites worldwide, #1,414 in Biotechnology and Pharmaceuticals.
- Monthly visits19.2K
▼ 17.1% vs previous month
- Unique visitors10.8K
per month
- Global rank#1,138,420
among all websites
- Category rank#1,414
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.0
- Average visit1 min 00 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Ascendis Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| zealandpharma.com | 100% | 25.2K | #1,273,571 | View details | |
| midas-pharma.com | 90% | #1,720,721 | View details | ||
paripharma.com | paripharma.com | 89% | – | ||
leo-pharma.dk | leo-pharma.dk | 88% | – | ||
| eyegatepharma.com | 87% | 5.3K | #2,931,419 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Ascendis Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ascendis Pharma
Complete news archive for Ascendis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ascendis Pharma
Ascendis Pharma was founded in 2007.
Ascendis Pharma is headquartered in Hellerup, Denmark.
Jan Moller Mikkelsen is the CEO of Ascendis Pharma, as recorded in our data.
Ascendis Pharma is a funded company, having raised a total of $108.7M across 3 funding rounds to date. The company's 1st funding round was a Series A of $25.8M, raised on Dec 2007.
Annual revenue of Ascendis Pharma is $812.73M as on Dec 31, 2025.
Ascendis Pharma was founded in 2007 in Hellerup, Denmark, as a biopharmaceutical company focused on prodrug technologies. Unmet medical needs are addressed through a pipeline that includes TransCon human growth hormone for growth hormone deficiency in adults and children, TransCon Treprostinil for pulmonary arterial hypertension, TransCon Insulin for diabetes, and TransCon Ranibizumab for age-related macular edema. Strategic collaborations are maintained with Sanofi and Genentech to support development efforts.
Yes, Ascendis Pharma is publicly traded on NASDAQ under the ticker symbol ASND.
Ascendis Pharma has 12 investors. Key investors include Orbimed, Janus Henderson Investors, RA Capital, Sofinnova, and Venrock.
Ascendis Pharma operates through Ascendis Pharma A/S.